Marshall P. Goren - Concepedia

Author

Marshall P. Goren

St. Jude Children's Research Hospital ORCID

Also Known As

H H Hansen, M Goren, M P Goren, M. Goren, M. P. Goren, M.P. Goren, MARSHALL P. GOREN, Marshall P. Goren

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

St. Jude Children's Research Hospital University of Tennessee Health Science Center University of Michigan University of Tennessee at Knoxville

About

Marshall P. Goren is an author at St. Jude Children's Research Hospital specializing in medicine, pharmacology, and nephrology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	815
2	Biochemistry	3	3	72
3	Health Sciences	2	2	86
4	Endocrinology	1	1	24
5	Hepatology	1	1	18

Marshall P. Goren

Publications

879

Citations

H-Index

Page 1

	Year	Citations
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Marshall P. Goren, Reba K. Wright, Charles B. Pratt, PubMed UrologyOncologyIfosfamide NeurotoxicityPrior TherapyMetronomic Therapy	1987	112
Cumulative renal tubular damage associated with cisplatin nephrotoxicity Marshall P. Goren, Reba K. Wright, Marc E. Horowitz Cancer Chemotherapy and Pharmacology UrologyRenal DiseasePathologyAcute Kidney InjuryCisplatin Nephrotoxicity	1986	94
Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. A A Forastiere, J. Belliveau, Marshall P. Goren, PubMed Neck CancerPharmacotherapyToxicity EvaluationToxicologyHepatotoxicity	1988	88
Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. C B Pratt, Marshall P. Goren, William H. Meyer, Journal of Clinical Oncology Pediatric Solid TumorsRelative RiskPharmacotherapyPrevious Cisplatin DosagesOncology	1990	68
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck. Arlene A. Forastiere, Ronald B. Natale, Bonnie J. Takasugi, Journal of Clinical Oncology Incurable HeadNeck CancerPathologyMetronomic ChemotherapyHematological Malignancy	1987	55
Ifosfamide in pediatric malignant solid tumors C B Pratt, E C Douglass, Erlinda Etcubanas, Cancer Chemotherapy and Pharmacology Surgical OncologyMedicinePathologyOncologyMalignant Disease	1989	43
Tubular nephrotoxicity during long-term ifosfamide and mesna therapy Marshall P. Goren, Charles B. Pratt, Mary Jane Viar Cancer Chemotherapy and Pharmacology Renal FunctionMedicinePharmacologyRenal PathophysiologyChronic Kidney Disease	1989	39
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity Marshall P. Goren, Arlene A. Forastiere, Reba K. Wright, Cancer Chemotherapy and Pharmacology Tubular NephrotoxicityRenal FunctionPharmacologyHigh Dose CisplatinPharmacotherapy	1987	32
A peroxidase-coupled kinetic enzymatic procedure evaluated for measuring serum and urinary creatinine. Marshall P. Goren, S Osborne, Reba K. Wright Clinical Chemistry Automated DeterminationUrologyRenal FunctionBiochemistryMedicine	1986	32
The Coomassie Brilliant Blue method underestimates drug-induced tubular proteinuria. Marshall P. Goren, J T Li Clinical Chemistry Cbb MethodRenal PathologyDrug-induced Tubular ProteinuriaGlomerulonephritisRenal Function	1986	31

Page 1